Autopsy report · NCT03700723

Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

“Convenience of Government Funding Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Entegrion, Inc.

Sponsor type

Industry

Conditions

Coagulopathy

Interventions

Resusix; FP24 (Frozen Plasma)

Participants

4

Sites

3

Countries

United States

Trials that died the same way

• WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease
  “funding purposes” (76% match in meaning)
• Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients
  “Curtailment of funding by sponsor” (73% match in meaning)
• A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
  “Sponsor decision - funding issues” (72% match in meaning)
• Cannabinoids for Taxane Induced Peripheral Neuropathy
  “Funding being sought” (71% match in meaning)
• Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
  “Decision by funding sponsor due to poor accrual” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.